Background: Relapsing polychondritis (RP) with airway involvement is a devastating disease leading to structural collapse and respiratory failure. Research is hampered by the lack of simple, stable animal models. We established a patient-derived 3D lung model to elucidate RP airway pathogenic mechanisms and identify therapeutic targets. Methods: Primary airway epithelial cells obtained via bronchial brushing from RP patients and healthy controls were differentiated at air-liquid interface (ALI) to form 3D epithelia. Morphology was assessed by histology. RNA sequencing of ALI cultures and plasma proteomics of patients were performed. Functional validation was conducted using specific inhibitors targeting the identified pathway. Results: Compared to controls, RP epithelia exhibited disrupted architecture, hyperproliferation, and increased senescence markers (e.g., p16, SA-β-gal). Multi-omics integration revealed significant activation of the ROCK1 signalling pathway in RP epithelia. This activation drove upregulation of peptidylarginine deiminase (PAD), leading to accelerated histone citrullination accumulation, a novel mechanism linking to cellular senescence and dysfunction. Targeted intervention using a ROCK1 inhibitor or a PAD inhibitor during ALI differentiation for two weeks significantly improved epithelial cell alignment, morphology, and barrier function in RP cultures. Conclusions: This patient-derived 3D model overcomes historical model limitations. The ROCK1-PAD-histone citrullination axis drives RP airway epithelial senescence and dysfunction, and its pharmacological inhibition rescues epithelial defects, highlighting ROCK1/PAD as promising therapeutic targets for treatment-refractory RP airway disease.